NR

NAD⁺ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence.

1. Ageing Res Rev. 2026 Apr;116:103057. doi: 10.1016/j.arr.2026.103057. Epub 2026 Feb 6. NAD⁺ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence. Gallagher C(1), Emmanuel OO(2). Author information: (1)Allure Management, 150 Allend

The Effect of Nicotinamide Mononucleotide and Riboside on Skeletal Muscle Mass and Function: A Systematic Review and Meta-Analysis.

2. J Cachexia Sarcopenia Muscle. 2025 Jun;16(3):e13799. doi: 10.1002/jcsm.13799. The Effect of Nicotinamide Mononucleotide and Riboside on Skeletal Muscle Mass and Function: A Systematic Review and Meta-Analysis. Prokopidis K(1), Moriarty F(2), Bahat G(3), McLean J(4), Church DD(5), Patel HP(6)(

Supplementation with NAD+ Precursors for Treating Alzheimer's Disease: A Metabolic Approach.

3. J Alzheimers Dis. 2024;101(s1):S467-S477. doi: 10.3233/JAD-231277. Supplementation with NAD+ Precursors for Treating Alzheimer's Disease: A Metabolic Approach. Alghamdi M(1)(2), Braidy N(1). Author information: (1)Centre for Healthy Brain Ageing, School of Psychiatry, University of New South

Impact of nutraceuticals and dietary supplements on mitochondria modifications in healthy aging: a systematic review of randomized controlled trials.

4. Aging Clin Exp Res. 2022 Nov;34(11):2659-2674. doi: 10.1007/s40520-022-02203-y. Epub 2022 Aug 3. Impact of nutraceuticals and dietary supplements on mitochondria modifications in healthy aging: a systematic review of randomized controlled trials. Lippi L(1)(2), Uberti F(3), Folli A(4), Turco

Gene expression profiles in sporadic ALS fibroblasts define disease subtypes and the metabolic effects of the investigational drug EH301.

5. Hum Mol Genet. 2022 Oct 10;31(20):3458-3477. doi: 10.1093/hmg/ddac118. Gene expression profiles in sporadic ALS fibroblasts define disease subtypes and the metabolic effects of the investigational drug EH301. Fels JA(1)(2), Casalena G(1), Konrad C(1), Holmes HE(3), Dellinger RW(3), Manfredi G

NAD+ therapy in age-related degenerative disorders: A benefit/risk analysis.

6. Exp Gerontol. 2020 Apr;132:110831. doi: 10.1016/j.exger.2020.110831. Epub 2020 Jan 7. NAD+ therapy in age-related degenerative disorders: A benefit/risk analysis. Braidy N(1), Liu Y(2). Author information: (1)Centre for Healthy Brain Ageing, School of Psychiatry, University of New South Wale

Safety and efficacy of individualised exercise and NAD(+) precursor supplementation in patients with Friedreich's ataxia in the USA: a single-centre, 2 × 2 factorial, randomised controlled trial.

7. Lancet Neurol. 2026 May;25(5):469-481. doi: 10.1016/S1474-4422(26)00082-7. Safety and efficacy of individualised exercise and NAD(+) precursor supplementation in patients with Friedreich's ataxia in the USA: a single-centre, 2 × 2 factorial, randomised controlled trial. Lin KY(1), Bucha A(1),

LRRK2-targeting antisense oligonucleotide in Parkinson's disease: a phase 1 randomized controlled trial.

8. Nat Med. 2026 Apr;32(4):1421-1431. doi: 10.1038/s41591-026-04262-4. Epub 2026 Mar 24. LRRK2-targeting antisense oligonucleotide in Parkinson's disease: a phase 1 randomized controlled trial. Mabrouk OS(1), Tichler B(2), Arnold HM(3), Thoma EC(2), Alexanian SM(3), Chen J(3), Liu TY(3), Hirsch

The differential impact of three different NAD(+) boosters on circulatory NAD and microbial metabolism in humans.

9. Nat Metab. 2026 Jan;8(1):62-73. doi: 10.1038/s42255-025-01421-8. Epub 2026 Jan 15. The differential impact of three different NAD(+) boosters on circulatory NAD and microbial metabolism in humans. Christen S(1), Redeuil K(1), Goulet L(1), Giner MP(1), Breton I(1), Rota R(1), Frézal A(1), Naz

Evaluation of Nicotinamide Riboside in Prevention of Small Nerve Fiber Axon Degeneration and Promotion of Nerve Regeneration.

10. J Peripher Nerv Syst. 2026 Mar;31(1):e70101. doi: 10.1111/jns.70101. Evaluation of Nicotinamide Riboside in Prevention of Small Nerve Fiber Axon Degeneration and Promotion of Nerve Regeneration. Thomas S(1), Ben-Davies R(1), Cetinkaya-Fisgin A(1), Hu X(1)(2), Li X(1), Stewart S(1), Pan B(1),

Nicotinamide riboside combined with exercise to treat hypertension in middle-aged and older adults: a pilot randomized clinical trial.

11. Geroscience. 2025 Dec;47(6):6895-6908. doi: 10.1007/s11357-025-01815-2. Epub 2025 Aug 7. Nicotinamide riboside combined with exercise to treat hypertension in middle-aged and older adults: a pilot randomized clinical trial. Lin Y(#)(1), Zeidan RS(#)(2)(3), Lapierre-Nguyen S(4), Costello HM(2

Nicotinamide Riboside Supplementation Benefits in Patients With Werner Syndrome: A Double-Blind Randomized Crossover Placebo-Controlled Trial.

12. Aging Cell. 2025 Aug;24(8):e70093. doi: 10.1111/acel.70093. Epub 2025 Jun 3. Nicotinamide Riboside Supplementation Benefits in Patients With Werner Syndrome: A Double-Blind Randomized Crossover Placebo-Controlled Trial. Shoji M(1)(2)(3), Kato H(1)(2), Koshizaka M(1)(4), Kaneko H(1)(2), Baba Y

Effect of nicotinamide riboside on airway inflammation in COPD: a randomized, placebo-controlled trial.

13. Nat Aging. 2024 Dec;4(12):1772-1781. doi: 10.1038/s43587-024-00758-1. Epub 2024 Nov 15. Effect of nicotinamide riboside on airway inflammation in COPD: a randomized, placebo-controlled trial. Norheim KL(1)(2)(3), Ben Ezra M(1), Heckenbach I(4), Andreasson LM(2)(3), Eriksen LL(2)(3), Dyhre-P

Feasibility of telehealth exercise and nicotinamide riboside supplementation in survivors of childhood cancer at risk for diabetes: A pilot randomized controlled trial.

14. Pediatr Blood Cancer. 2025 Jan;72(1):e31369. doi: 10.1002/pbc.31369. Epub 2024 Oct 10. Feasibility of telehealth exercise and nicotinamide riboside supplementation in survivors of childhood cancer at risk for diabetes: A pilot randomized controlled trial. Bhandari R(1)(2), Lukas K(1), Lee K

Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial.

15. Nat Commun. 2024 Jun 13;15(1):5046. doi: 10.1038/s41467-024-49092-5. Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial. McDermott MM(1)(2), Martens CR(3), Domanchuk KJ(4), Zhang D(4), Peek CB(4)(5), Criqui MH(6), Ferrucci L(7), Greenland P(4)(8), Guralni

NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson's disease.

41. Nat Commun. 2023 Nov 28;14(1):7793. doi: 10.1038/s41467-023-43514-6. NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson's disease. Berven H(1)(2)(3), Kverneng S(1)(2)(3), Sheard E(1), Søgnen M(1), Af Geijerstam SA(1), Haugarvoll K(1), Skeie GO(1)

An integrated anti-aging framework targeting NAD(+) homeostasis, mitochondrial quality control, and redox stability: Roles of NMN/NR, PQQ, and EGT.

45. Redox Biol. 2026 Apr 24;93:104191. doi: 10.1016/j.redox.2026.104191. Online ahead of print. An integrated anti-aging framework targeting NAD(+) homeostasis, mitochondrial quality control, and redox stability: Roles of NMN/NR, PQQ, and EGT. Sun Y(1), Han JC(1), Tran K(1), Pham T(2), Zhou Q(3)

NAD+ augmentation by nicotinamide riboside engages SLIT2/ROBO1 signaling to attenuate Th17 inflammation in psoriasis.

26. JCI Insight. 2026 Apr 28:e203826. doi: 10.1172/jci.insight.203826. Online ahead of print. NAD+ augmentation by nicotinamide riboside engages SLIT2/ROBO1 signaling to attenuate Th17 inflammation in psoriasis. Han K(1), Klein RJ(1), Recupero TC(1), Russo AC(1), Sharma R(1), Gupta AK(1), Hassa

Nicotinamide Riboside (NR) Supplementation Exerts Neuroprotective Effects in db/db Mouse Model of Type 2 Diabetes.

9. J Mol Neurosci. 2026 Apr 27;76(2):70. doi: 10.1007/s12031-026-02499-9. Nicotinamide Riboside (NR) Supplementation Exerts Neuroprotective Effects in db/db Mouse Model of Type 2 Diabetes. Hughes E(#)(1), Barton K(#)(2), Rizvi D(3), Dial K(3), Wang XX(3), Myakala K(3), Harris BT(3), Rebeck GW(3)

SRN-901, a Novel Longevity Drug, Extends Lifespan and Healthspan by Targeting Multiple Aging Pathways.

18. Drug Des Devel Ther. 2026 Apr 15;20:594895. doi: 10.2147/DDDT.S594895. eCollection 2026. SRN-901, a Novel Longevity Drug, Extends Lifespan and Healthspan by Targeting Multiple Aging Pathways. Weiss B(1), Miranda DR(1), Arrazati D(1), Cao R(1), Chen J(2)(3), Liu Y(3)(4), Brown D(1), Marshall

NAD(+) precursor supplementation reverses CD36-mediated lipid accumulation and ferroptosis to restore antitumor function of NK cells in DLBCL.

34. Pharm Sci Adv. 2026 Feb 12;4:100111. doi: 10.1016/j.pscia.2026.100111. eCollection 2026 Dec. NAD(+) precursor supplementation reverses CD36-mediated lipid accumulation and ferroptosis to restore antitumor function of NK cells in DLBCL. Shi L(1), Huang X(1), Han X(2), Ning C(2), Zhao X(2), Li

Long-term region-specific mitochondrial respiration impairment after perinatal asphyxia is prevented by the NAD⁺ donor nicotinamide riboside: A real-time organotypic metabolic profiling approach.

39. Pharmacol Res. 2026 May;227:108190. doi: 10.1016/j.phrs.2026.108190. Epub 2026 Apr 13. Long-term region-specific mitochondrial respiration impairment after perinatal asphyxia is prevented by the NAD⁺ donor nicotinamide riboside: A real-time organotypic metabolic profiling approach. Díaz-Urb

NAD(+) Enhancer Nicotinamide Riboside Alters Extracellular Purine Metabolism in Human Endothelial Cells.

16. Int J Mol Sci. 2026 Apr 3;27(7):3267. doi: 10.3390/ijms27073267. NAD(+) Enhancer Nicotinamide Riboside Alters Extracellular Purine Metabolism in Human Endothelial Cells. Harasim-Krawcewicz G(1), Mierzejewska P(1)(2), Kawecka A(1)(2), Frańczak MA(1)(2), Król O(1), Presler M(1), Jędrzejewska A

Effects of NAD⁺ repletion with Nicotinamide riboside on obesity-induced chronic kidney disease and renal cell lipotoxicity.

40. Sci Rep. 2026 Apr 9. doi: 10.1038/s41598-026-46173-x. Online ahead of print. Effects of NAD⁺ repletion with Nicotinamide riboside on obesity-induced chronic kidney disease and renal cell lipotoxicity. Decarnoncle M(#)(1), Pierre L(#)(1)(2), Thirion M(1), Marlier H(1)(2), Maréchal L(1)(2), Ro

Effective oral countermeasures against ionizing radiation-induced damage without hindering cancer radiotherapy.

13. Biomed Pharmacother. 2026 May;198:119323. doi: 10.1016/j.biopha.2026.119323. Epub 2026 Apr 6. Effective oral countermeasures against ionizing radiation-induced damage without hindering cancer radiotherapy. López-Blanch R(1), Oriol-Caballo M(2), Salvador-Palmer R(3), Moreno-Murciano P(1), Be

Role of nicotinamide adenine dinucleotide in cardiovascular disease.

27. Curr Opin Cardiol. 2026 Apr 3. doi: 10.1097/HCO.0000000000001292. Online ahead of print. Role of nicotinamide adenine dinucleotide in cardiovascular disease. Prasanna J(1), Manickam R, Tipparaju SM. Author information: (1)Department of Pharmaceutical Sciences, USF Health Taneja College of Ph

Finishing Barrow Skeletal Muscle Performance and Fatigue Response to Large-Dose Nicotinamide Riboside Supplementation.

47. Metabolites. 2026 Apr 13;16(4):261. doi: 10.3390/metabo16040261. Finishing Barrow Skeletal Muscle Performance and Fatigue Response to Large-Dose Nicotinamide Riboside Supplementation. Alambarrio DA(1), Li X(1), Zedonek SS(1), Willis SE(1), Proctor JN(1), Mozafari F(2), Call JA(2)(3), Delgado

Endothelial NAD(+) depletion drives vascular senescence and neuroinflammation via mtDNA-cGAS/STING-CD38 signaling in Alzheimer's disease.

40. Alzheimers Dement. 2026 Apr;22(4):e71423. doi: 10.1002/alz.71423. Endothelial NAD(+) depletion drives vascular senescence and neuroinflammation via mtDNA-cGAS/STING-CD38 signaling in Alzheimer's disease. Luo QH(1)(2), Li F(1), Yang L(2)(3), Pan HQ(1), Zhu WP(2)(3), Hu P(2)(3), Tao CM(1)(2),

Dietary Bioactives in Alzheimer's Disease: A Critical Appraisal of Clinical Trials and Future Nutritional Strategies.

29. Nutrients. 2026 Mar 12;18(6):907. doi: 10.3390/nu18060907. Dietary Bioactives in Alzheimer's Disease: A Critical Appraisal of Clinical Trials and Future Nutritional Strategies. Kumari A(1)(2), Zeng XA(1)(2)(3)(4). Author information: (1)School of Food Science and Engineering, South China Uni

The NAD-brain pharmacokinetic study of NAD augmentation in blood and brain using oral precursor supplementation.

1. iScience. 2026 Jan 27;29(3):114764. doi: 10.1016/j.isci.2026.114764. eCollection 2026 Mar 20. The NAD-brain pharmacokinetic study of NAD augmentation in blood and brain using oral precursor supplementation. Berven H(1)(2)(3), Svensen M(1)(2)(4), Eikeland H(1), Tvedten N(1), Sheard EV(1), Af